Phillipps H.R., Yip S.H., Grattan D.R. Patterns of prolactin secretion. Mol Cell Endocrinol 2020;502:10679.
DOI: 10.1016/j.mce.2019.110679

Rohn R.D. Galactorrhea in the adolescent. J Adolesc Health Care 1984;5(1):37–49.
DOI: 10.1016/s0197-0070(84)80244-2

Cabrera-Reyes E.A., Limón-Morales O., Rivero-Segura N.A. et al. Prolactin function and putative expression in the brain. Endocrinology 2017;57(2):199–213.
DOI: 10.1007/s12020-017-1346-x

Paragliola R.M., Binart N., Salvatori R. Prolactin. In: The Pituitary. Ed. by S. Melmed. 5th edn. Academic Press, 2022. P. 131–172.
DOI: 10.1016/B978-0-323-99899-4.00025-1

Macotela Y., Ruiz-Herrera X., Vázquez-Carrillo D.I. et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne) 2022;13:1001703.
DOI: 10.3389/fendo.2022.1001703

Lopez-Vicchi F., De Winne C., Brie B. et al. Metabolic functions of prolactin: Physiological and pathological aspects. Neuroendocrinol 2020;32(11):e12888.
DOI: 10.1111/jne.12888

Адамян Л.В., Ярмолинская М.И., Суслова Е.В. Синдром гиперпролактинемии: от теории к практике. Проблемы репродукции 2020;26(2):27–33.
DOI: 10.17116/repro20202602127

Bernard V., Young J., Binart N. Prolactin – a pleiotropic factor in health and disease. Nat Rev Endocrinol 2019;15(6):356–65.
DOI: 10.1038/s41574-019-0194-6

Pirchio R., Graziadio C., Colao A. et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne) 2022;13:1015520.
DOI: 10.3389/fendo.2022.1015520

Rastrelli G., Corona G., Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord 2015;16(3):233–48.
DOI: 10.1007/s11154-015-9322-3

Al-Karagholi M.A., Kalatharan V., Ghanizada H. et al. Prolactin in headache and migraine: a systematic review of clinical studies. Cephalalgia 2023;43(2):3331024221136286.
DOI: 10.1177/03331024221136286

Grattan D.R. Coordination or coincidence? The relationship between prolactin and gonadotropin secretion. Trends Endocrinol Metab 2018;29(1):3–5.
DOI: 10.1016/j.tem.2017.11.004

Clarkson J., Han S.Y., Piet R. et al. Definition of the hypothalamic GnRH pulse generator in mice. Proc Natl Acad Sci U S A 2017; 114(47):E10216–23.
DOI: 10.1073/pnas.1713897114

Dabbous Z., Atkin S.L. Hyperprolactinaemia in male infertility: clinical case scenarios. Arab J Urol 2017;16(1):44–52.
DOI: 10.1016/j.aju.2017.10.002

Gonzales G.F., Velasquez G., Garcia-Hjarles M. Hypoprolactinemia as related to seminal quality and serum testosterone. Arch Androl 1989;23(3):259–65.
DOI: 10.3109/01485018908986849

Firdolas F., Ogras M.S., Ozan T. et al. In vitro examination of effects of hyperprolactinemia and hypoprolactinemia on seminal vesicle contractions. Urol 2013;81(3):557–61.
DOI: 10.1016/j.urology.2012.11.025

Sengupta P., Dutta S., Karkada I.R., Chinni S.V. Endocrinopathies and male infertility. Life (Basel) 2021;12(1):10.
DOI: 10.3390/life12010010

Vander B.M., Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem 2018;62:2–10.
DOI: 10.1016/j.clinbiochem.2018.03.012

Ambulkar S.S., Darves-Bornoz A.L., Fantus R.J. et al. Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation. Urology 2022;159:114–9.
DOI: 10.1016/j.urology.2021.03.007

Samperi I., Lithgow K., Karavitaki N. Hyperprolactinaemia. J Clin Med 2019;8(12):2203.
DOI: 10.3390/jcm8122203

Corona G., Isidori A.M., Aversa A. et al. Endocrinologic control of men’s sexual desire and arousal/erection. J Sex Med 2016;13(3):317–37.
DOI: 10.1016/j.jsxm.2016.01.007

Krysiak R., Okopień B. Sexual functioning in hyperprolactinemic patients treated with cabergoline or bromocriptine. Am J Ther 2019;26(4):e433–40.
DOI: 10.1097/MJT.0000000000000777

Fiala L., Lenz J., Sajdlova R. Effect of increased prolactin and psychosocial stress on erectile function. Andrologia 2021;53(4):e14009.
DOI: 10.1111/and.14009.

Xu Z.H., Pan D., Liu T.Y. et al. Effect of prolactin on penile erection: a cross-sectional study. Asian J Androl 2019;21(6):587–91.
DOI: 10.4103/aja.aja_22_19

Corona G., Mannucci E., Jannini E.A. et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med 2009;6(5):1457–66.
DOI: 10.1111/j.1743-6109.2008.01206.x

Corona G., Rastrelli G., Comeglio P. et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab 2022;17(6):533–45.
DOI: 10.1080/17446651.2022.2144829

Krysiak R., Kowalcze K., Okopień B. Sexual function and depressive symptoms in men with hypoprolactinaemia secondary to overtreatment of prolactin excess: a pilot study. Endocrinol Diabetes Nutr (Engl Ed) 2022:69(4):279–88.
DOI: 10.1016/j.endien.2021.03.004

Maurya M.R, Munshi R., Zambare S. Melanocortin receptors: emerging targets for the treatment of pigmentation, inflammation, stress, weight disorders and sexual dysfunction. Curr Drug Targets 2023;24(2):151–6.
DOI: 10.2174/1389450124666221108143006

Rahmani B., Ghasemi R., Dargahi L. et al. Neurosteroids; potential underpinning roles in maintaining homeostasis. Gen Comp Endocrinol 2016;225:242–50.
DOI: 10.1016/j.ygcen.2015.09.030

Goffin V. Prolactin receptor targeting in breast and prostate cancers: new insights into an old challenge. Pharmacol Ther 2017;179:111–26.
DOI: 10.1016/j.pharmthera.2017.05.009

Karayazi Atıcı Ö., Govindrajan N., Lopetegui-González I., Shemanko C.S. Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis. Semin Cell Dev Biol 2021;114:159–70.
DOI: 10.1016/j.semcdb.2020.10.005

Costello L.C., Franklin R.B. Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm Metab Res 2002;34(8):417–24.
DOI: 10.1055/s-2002-33598

Camargo A.C.L., Constantino F.B., Santos S.A.A. et al. Influence of postnatal prolactin modulation on the development and maturation of ventral prostate in young rats. Reprod Fertil Dev 2018;30(7): 969–79.
DOI: 10.1071/RD17343

López Fontana G., Rey L., Santiano F. et al. Changes in prolactin receptor location in prostate tumors. Arch Esp Urol 2021;74(4):419–26

La Vignera S., Condorelli R.A., Russo G.I. et al. Endocrine control of benign prostatic hyperplasia. Andrology 2016;4(3):404–11.
DOI: 10.1111/andr.12186

Loutchanwoot P., Srivilai P., Jarry H. Effects of the natural endocrine disruptor equol on the pituitary function in adult male rats. Toxicol 2013;304:69–75.
DOI: 10.1016/j.tox.2012.11.017

Govindaraj V., Arya S.V., Rao A.J. Differential action of glycoprotein hormones: significance in cancer progression. Horm Cancer 2014;5(1):1–10.
DOI: 10.1007/s12672-013-0164-8

Slaunwhite W.R. Jr., Sharma M. Effects of hypophysectomy and prolactin replacement therapy on prostatic response to androgen in orchiectomized rats. Biol Reprod 1977;17(4):489–92.
DOI: 10.1095/biolreprod17.4.489

Rui H., Purvis K. Independent control of citrate production and ornithine decarboxylase by prolactin in the lateral lobe of the rat prostate. Mol Cell Endocrinol 1987;52(1–2):91–5.
DOI: 10.1016/0303-7207(87)90101-8

Zanatelli M., Colleta S.J., Guerra L.H.A. et al. Prolactin promotes a partial recovery from the atrophy of both male and female gerbil prostates caused by castration. Reprod Biol Endocrinol 2021;19(1):94.
DOI: 10.1186/s12958-021-00777-2

Constantino F.B., Camargo A.C.L., Santos S.A.A. et al. The prostate response to prolactin modulation in adult castrated rats subjected to testosterone replacement. J Mol Histol 2017;48(5–6): 403–15.
DOI: 10.1007/s10735-017-9738-z

Costello L.C., Franklin R.B. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: testosterone-independent malignancy is the development of prolactin-dependent malignancy. Oncol Rev 2018;12(2):356.
DOI: 10.4081/oncol.2018.356

Di Zazzo E., Galasso G., Giovannelli P. et al. Estrogens and their receptors in prostate cancer: therapeutic implications. Front Oncol 2018;8:2.
DOI: 10.3389/fonc.2018.00002

Dobbs R.W., Malhotra N.R., Greenwald D.T. et al. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis 2019;22(2):185–94.
DOI: 10.1038/s41391-018-0081-6

Van Coppenolle F., Slomianny C., Carpentier F. et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001;280(1):E120–9.
DOI: 10.1152/ajpendo.2001.280.1.E120

Zhang Y., Gc S., Patel S.B. et al. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R). Mol Cell Endocrinol 2019;492:110445.
DOI: 10.1016/j.mce.2019.05.004

Kavarthapu R., Anbazhagan R., Dufau M.L. Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast cancer. Cancers (Basel) 2021;13(18):4685.
DOI: 10.3390/cancers13184685

Borcherding D.C., Hugo E.R., Fox S.R. et al. Suppression of breast cancer by small molecules that block the prolactin receptor. Cancers (Basel) 2021;13(11):2662.
DOI: 10.3390/cancers13112662

Sackmann-Sala L., Goffin V. Prolactin-induced prostate tumorigenesis. Adv Exp Med Biol 2015;846:221–42.
DOI: 10.1007/978-3-319-12114-7_10

Minami H., Ando Y., Tamura K. et al. Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer. Anticancer Res 2020;40(9):5229–35.
DOI: 10.21873/anticanres.14526

Agarwal N., Machiels J.P., Suárez C. et al. Phase I study of the prolactin receptor antagonist LFA102 in metastatic breast and castration-resistant prostate cancer. Oncologist 2016;21(5):535–6.
DOI: 10.1634/theoncologist.2015-0502

Carrasco-Ceballos J.M., Barrera-Hernández D., Locia-Espinosa J. et al. Involvement of the PRL-PAK1 pathway in cancer cell migration. Cancer Diagn Progn 2023;3(1):17–25.
DOI: 10.21873/cdp.10174

Standing D., Dandawate P., Anant S. Prolactin receptor signaling: a novel target for cancer treatment – exploring anti-PRLR signaling strategies. Front Endocrinol (Lausanne) 2023;13:1112987.
DOI: 10.3389/fendo.2022.1112987

Costello L.C. The suppression of prolactin is required for the treatment of advanced prostate cancer. Oncogen (Westerville) 2019;2(3):13.
DOI: 10.35702/onc.10013

Porcaro A.B., Tafuri A., Sebben M. et al. Low preoperative prolactin levels predict non-organ confined prostate cancer in clinically localized disease. Urol Int 2019;103(4):391–9.
DOI: 10.1159/000496833

Costello L.C., Franklin R.B. A proposed efficacious treatment with clioquinol (zinc ionophore) and cabergoline (prolactin dopamine agonist) for the treatment of terminal androgen-independent prostate cancer. Why and how? J Clin Res Oncol 2019;2(1):https://asclepiusopen.com/journal-of-clinical-research-in-оncology/ volume-2-issue-1/1.pdf

Yang T., Liu Y., Chen S. et al. Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. Prostate 2022;82(13):1284–92.
DOI: 10.1002/pros.24402

Ma J., Mo Y., Tang M. et al. Bispecific antibodies: аrom research to clinical application. Front Immunol 2021;12:626616.
DOI: 10.3389/fimmu.2021.626616

Anderson M.G., Zhang Q., Rodriguez L.E. et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer 2021;21(1):681.
DOI: 10.1186/s12885-021-08403-5

Lemech C., Woodward N., Chan N. et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibodydrug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs 2020;38(6):1815–25.
DOI: 10.1007/s10637-020-00960-z